STOCK TITAN

Hologic Inc - HOLX STOCK NEWS

Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.

Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.

Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.

Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.

Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.

Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.

Rhea-AI Summary
Hologic, Inc. (HOLX) will release its Q2 fiscal 2024 results on May 2, with a conference call at 4:30 p.m. ET. Interested parties can join via phone or webcast. Replay will be available on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
-
Rhea-AI Summary
Hologic, Inc. and Biotheranostics, Inc. announce study results showing 40% of patients with early-stage HR+ breast cancer had treatment recommendations changed based on the Breast Cancer Index test. The test helps identify women who may benefit from extended anti-estrogen therapy, avoiding both overtreatment and undertreatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) presents new research in artificial intelligence (AI) at the annual European Congress of Radiology, showcasing the potential of deep-learning solutions in breast cancer detection. Dr. Sarah M. Friedewald will discuss the impact of Hologic's Genius AI® Detection solution on workflow efficiency and patient care. The company also highlights the superiority of its AI algorithm over traditional CAD algorithms, emphasizing innovation and collaboration with Bayer on contrast-enhanced mammography.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
AI
Rhea-AI Summary
Hologic, Inc. (HOLX) to present at Raymond James' Institutional Investors Conference and Needham Virtual Healthcare Conference. Webcasts available for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
conferences
-
Rhea-AI Summary
Hologic, Inc. has received FDA clearance for its Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm, the first FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
none
-
Rhea-AI Summary
Hologic, Inc. (HOLX) reported revenue of $1,013.1 million, GAAP Diluted EPS of $1.03, and Non-GAAP Diluted EPS of $0.98, exceeding guidance. The company saw a 5.2% organic revenue growth excluding COVID-19, and delivered strong results in Breast Health and Surgical divisions. The financials for the first quarter of 2024 showed a decrease in revenue, primarily due to lower sales of COVID-19 assays compared to the prior year period. The company executed a $500 million accelerated share repurchase agreement (ASR), repurchased 2.2 million shares of its stock in open market trades for $150 million, and paid down $250 million of outstanding floating rate debt under its credit agreement. The company provided guidance for the second quarter and full year 2024, showing a strong outlook for fiscal 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
Rhea-AI Summary
The third annual Hologic Global Women’s Health Index reveals concerning trends in women's health, including billions of women untested for life-threatening conditions, worsening emotional health, and nearly 1 billion women living with physical pain. Taiwan tops the rankings of women’s health by country/territory, while the U.S. falls to number 30. Hologic, Inc. (Nasdaq: HOLX) partnered with Gallup to create the Index, which was launched at the World Economic Forum in Davos, Switzerland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
covid-19
-
Rhea-AI Summary
Company XYZ, a leading women's health company (Ticker: XYZ), urges women to openly discuss their health issues with their doctors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none
-
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) reported preliminary revenue results for its first fiscal quarter ended December 30, 2023, totaling approximately $1,013.1 million, exceeding the most recent revenue guidance range of $960 to $985 million. Despite a decrease compared to the prior year period, the company achieved 5.2% organic constant currency revenue growth, surpassing expectations. The company's Chairman, President, and CEO, Steve MacMillan, emphasized strong organic revenue performance, estimating over 9% growth in total company organic revenue excluding COVID-19. The preliminary results highlight divisional revenue changes, with Breast Health showing significant growth of 13.0% and GYN Surgical growing by 5.3%. Hologic expects non-GAAP diluted earnings per share (EPS) to be towards the high-end of the guidance range of $0.92 to $0.97 and plans to provide full financial results on February 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) will release its first quarter fiscal 2024 financial results on February 1, after the market closes. Management will host a conference call at 4:30 p.m. Eastern Time. Interested participants can join the call by dialing (888) 394-8218 (US and Canada) or +1 (773) 305-6853 (international callers) with access code 5909239. A live and webcast replay will be available on the Company’s website at https://investors.hologic.com for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags

FAQ

What is the current stock price of Hologic (HOLX)?

The current stock price of Hologic (HOLX) is $71.65 as of December 20, 2024.

What is the market cap of Hologic (HOLX)?

The market cap of Hologic (HOLX) is approximately 16.1B.

What does Hologic Inc. specialize in?

Hologic Inc. specializes in developing, marketing, and servicing innovative and accurate diagnostic imaging systems and surgical products, with a focus on women's healthcare.

Where is Hologic Inc. headquartered?

Hologic Inc. is headquartered in Bedford, Massachusetts.

What are the main segments of Hologic’s business?

Hologic operates in five main segments: diagnostics, breast health, surgical, and skeletal health.

Which segment contributes the most to Hologic's revenue?

The diagnostics segment contributes the most, accounting for 60% of Hologic's total sales.

How has the pandemic affected Hologic’s business segments?

The pandemic boosted the diagnostics segment but initially suppressed the breast health segment.

What percentage of Hologic’s revenue comes from the United States?

69% of Hologic’s revenue comes from the United States.

How did the acquisition of Gen-Probe impact Hologic?

The acquisition of Gen-Probe shifted Hologic’s focus more towards commercial diagnostics.

How can I stay updated with Hologic's latest news?

You can stay updated by visiting Hologic's website, or following them on Facebook and Twitter.

What is Hologic’s approach to healthcare?

Hologic is dedicated to the science of sure, providing greater confidence and peace of mind in medical diagnosis to enable healthier lives.

What percentage of Hologic’s revenue comes from international markets?

Approximately 31% of Hologic’s revenue comes from international markets, including Europe, Asia, and other regions.

Hologic Inc

Nasdaq:HOLX

HOLX Rankings

HOLX Stock Data

16.11B
225.10M
0.8%
105.31%
1.98%
Medical Instruments & Supplies
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States of America
MARLBOROUGH